Welcome to our dedicated page for Angle Plc Surrey news (Ticker: ANPCF), a resource for investors and traders seeking the latest updates and insights on Angle Plc Surrey stock.
The ANPCF news page on Stock Titan aggregates regulatory announcements and market updates relating to CelLBxHealth plc, a precision circulating tumour cell (CTC) intelligence and liquid biopsy company previously known as ANGLE plc. Company news releases describe how CelLBxHealth develops and commercialises its Parsortix CTC harvesting platform, associated consumables and assays, and GCLP-compliant laboratory services for use in research, drug development and clinical oncology.
Readers can use this page to follow corporate developments such as strategy updates, name and ticker changes, board and management appointments, and changes in nominated adviser or broker. The feed also includes clinical and scientific milestones, for example proof-of-concept studies in specific tumour types, collaborations with large pharmaceutical and medtech companies, and presentations at international oncology and drug development conferences.
Because CelLBxHealth operates in the Diagnostics & Research segment of the healthcare sector, its news often highlights progress in CTC-based liquid biopsy, expert consensus publications on CTCs, and the integration of Parsortix-derived samples with proteomic and genomic workflows. Investors and researchers can track how the company positions its technology in relation to circulating tumour DNA (ctDNA), precision oncology and pharmaceutical services.
In addition, the news stream may contain capital markets disclosures such as interim results summaries, funding updates and notifications of major shareholdings. By reviewing these items together, users can build a picture of how CelLBxHealth’s CTC platform, service offerings and partnerships are evolving over time. Bookmark this page to access a consolidated view of ANPCF-related announcements drawn from recognised regulatory and news distribution channels.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.
An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.
ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.
On July 12, 2024, Angle PLC, a UK-based company, announced a significant change in its major shareholdings. Dermot Keane, based in London, UK, has crossed the 5% threshold, increasing his voting rights from 4.90% to 8.09%, amounting to 26,110,422 voting rights. The notification was triggered by an acquisition of voting rights, with the official threshold crossing occurring on June 5, 2024. This information was published through the London Stock Exchange's Regulatory News Service (RNS), approved by the Financial Conduct Authority (FCA). No other financial instruments or changes in voting rights breakdown were reported.
ANGLE plc, a leader in liquid biopsy solutions for CTCs, announced the posting of its 2023 Annual Report and Financial Statements. The report, covering the year ending December 31, 2023, is available on the company's website. Shareholders have been invited to the Annual General Meeting (AGM) scheduled for July 11, 2024, at the Surrey Technology Centre. The AGM will include a business update following formal proceedings. This announcement is significant for stakeholders tracking corporate governance and financial performance of ANGLE plc.
ANGLE announces the showcasing of its Parsortix system and assays at the European Association for Cancer Research (EACR) 2024 Annual Congress.
The company highlights two key presentations: the dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for genetic profiling in ovarian, breast, and lung cancer patients, and the use of its DNA Damage Response (DDR) assay to monitor treatment effectiveness in ovarian and prostate cancer patients.
The presentations demonstrate the Parsortix system's potential for personalized cancer treatment and therapeutic monitoring.
Summary not available.
Summary not available.
Summary not available.
Summary not available.